Momenta plans exit of Mylan biosimilars
Momenta Pharmaceuticals has “initiated discussions” with partner Mylan to exit its participation in the development of five biosimilar programs, including the firms’ M834 biosimilar Orencia (abatacept) candidate, after completing a strategic review “aimed at reducing costs of biosimilar development” and focusing its resources on its pipeline of novel drug candidates.
You may also be interested in...
Viatris Believes Eylea Biosimilar Candidate Is First To Reach US FDA’s Desk
Viatris provided several key updates for its biosimilar pipeline during the company’s Q3 earnings call, including for its biosimilar Eylea and Botox candidates, as well as disclosing another key early-stage asset.
Eylea Biosimilar Developer Momenta To Be Acquired By J&J For $6.5bn
Momenta Pharmaceuticals has signed an agreement to be acquired by Johnson & Johnson, with the deal to include, for now, the M710 biosimilar aflibercept candidate being developed with Mylan.
Momenta’s Decision To Ditch Abatacept Makes Orencia Dispute Moot
Abandoning development of a biosimilar removes any right to challenge patents protecting the reference biologic, the US Court of Appeals has stated in dismissing Momenta’s appeal over abatacept.